Roughly 38,000 papers were published on diabetes during 2016, which highlights the rich diversity of research ongoing and the progress made in treatment and management of the disease during this year.
We asked our Scientific Committee Members for Manage Diabetes Online, Professor Ruy Lyra (pictured at right) from Brazil and Professor Chaicharn Deerochanawong from Thailand to choose the papers from 2016 that, in their opinion, were the most important papers, or those that had made the most impact on the scientific community.
These papers are in no particular order
Ma RCW, Schmidt MI, Tam WH, et al. Clinical management of pregnancy in the obese mother: before conception, during pregnancy, and postpartum. Lancet Diabetes Endocrinol 2016;4:1037-1049. Published Online October 12, 2016 http://dx.doi.org/10.1016/ S2213-8587(16)30278-9.
“The medical and obstetric management of obese women is focused on identifying, addressing, and preventing associated complications, and is a daunting challenge given the high percentage of patients with obesity and few therapeutic options proven to improve outcomes in this population.”
Frandsen CS, Dejgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 2016;4:766–80. Published Online March 8, 2016 http://dx.doi.org/10.1016/S2213-8587(16)00039-5.
“A subgroup of patients with type 1 diabetes for whom non-insulin antidiabetic drugs could significantly benefit glycaemic control cannot yet be defined, but we suggest that obese patients prone to hypoglycaemia and patients with residual β-cell function are populations of interest for future trials.”
Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2016:37:536–45.
“In patients with primary hypercholesterolemia, proprotein convertase subtilisin-kexin type 9 serine protease inhibitors reduce all-cause mortality, but not CV events, and increase neurocognitive events.”
Wanner C, Inzucchi SE, Lachin JM, et al for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323-34. DOI: 10.1056/ NEJMoa1515920.
“In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.”
Marso SP, Bain SC, Consoli A, et al. for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 Sep 15. [Epub ahead of print] NEJM.org.DOI: 10.1056/ NEJMoa1607141.
“In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.”
Marso SP, Daniels GH, Brown-Frandsen K, et al for the LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;28;375:311-22.
“In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.”
These three studies (EMPA-REG OUTCOME, SUSTAIN-6 and LEADER) found benefits with drug treatment that were beyond the reduction of blood glucose, increasing, therefore, the benefits to proper use.